Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-02-28

Clinical Trial Update: CRT-Guanfacine for SPD [Phase 2]

View source ↗

Summary

A Phase 2 trial investigating CRT-Guanfacine for Schizotypal Personality Disorder has completed; the update does not include results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Guanfacine (guanfacine)

Snippet

Sponsor: Icahn School of Medicine at Mount Sinai | Conditions: Schizotypal Personality Disorder, SPD | Phase 2 | Status: COMPLETED